Table 4 Univariate analysis for overall survival and progression free survival in high-intermediate and high risk IPI patients
Median OS, months | HR (95% CI) | P-value | Median PFS, months | HR (95% CI) | P-value | |
|---|---|---|---|---|---|---|
Age | ||||||
< 60 years | 7.0 | 0.79 (0.39-1.61) | 0.512 | 2.9 | 0.50 (0.24-1.01) | 0.059 |
≥ 60 years | 9.2 | 9.6 | ||||
Gender | ||||||
Male | 10.1 | 1.33 (0.64-2.76) | 0.444 | 8.1 | 1.07 (0.29-2.29) | 0.862 |
Female | 5.2 | 3.5 | ||||
Performance status | ||||||
0-1 | 10.1 | 1.72 (0.79-3.73) | 0.168 | 8.1 | 1.15 (0.51-2.59) | 0.728 |
2-4 | 4.8 | 3.6 | ||||
B symptom | ||||||
Absent | 9.2 | 1.29 (0.62-2.66) | 0.490 | 8.1 | 1.09 (0.51-2.33) | 0.810 |
Present | 7.0 | 3.6 | ||||
Stage | ||||||
1-2 | 4.0 | 0.21(0.02-0.72) | 0.147 | 3.6 | 0.45 (0.05-3.44) | 0.445 |
3-4 | 9.2 | 8.1 | ||||
Extranodal involvement | ||||||
0-1 | 10.1 | 1.13 (0.56-2.28) | 0.729 | 14.7 | 1.27 (0.61-2.67) | 0.518 |
≥ 2 | 8.1 | 3.9 | ||||
Bone marrow involvement | ||||||
Negative | 11.9 | 1.33 (0.66-2.67) | 0.414 | 9.5 | 1.29 (0.64-2.61) | 0.467 |
Positive | 7.3 | 7.0 | ||||
LDH | ||||||
Normal | 9.2 | 1.51 (0.45-4.97) | 0.498 | 8.1 | 1.54 (0.46-5.10) | 0.474 |
Elevated | 7.6 | 7.3 | ||||
PIT | ||||||
Group 1-2 | 16.9 | 1.35 (0.58-3.14) | 0.476 | 8.1 | 1.06 (0.45-2.48) | 0.883 |
Group 3-4 | 7.6 | 7.3 | ||||
ALC | ||||||
≥ 1.0 × 109/l | 10.6 | 3.09 (1.52-6.32) | 0.002 | 11.9 | 4.02 (1.80-8.97) | 0.001 |
< 1.0 × 109/l | 4.0 | 2.9 |